Edmund P. Farris, M.D. is a Board Certified Ophthalmologist and glaucoma specialist who has been in practice since 1997. Dr. Farris received his undergraduate degree from Northwestern University and his medical degree from The Medical College of Ohio, where he was named to the Alpha Omega Alpha Medical Honor Society. He then completed his ophthalmology residency at New York Medical College where he served as chief resident. This was followed by a glaucoma fellowship at The Mount Sinai School of Medicine. Dr. Farris’ practice is focused on glaucoma subspecialty work, but he welcomes general ophthalmology patients as well. He is proud to offer his patients the best in the diagnosis and management of all types of glaucoma and associated ocular conditions, and has performed thousands of procedures during his 25 years of practice. In addition, Dr. Farris performs Intense Pulse Light (IPL) therapy for dry eye and numerous cosmetic applications, and has performed Botox injections for facial rejuvenation for over 20 years.
Dr. Farris, a Fellow of The American Academy of Ophthalmology and The American Glaucoma Society, has served as the Director of Glaucoma Services at Metropolitan Hospital, Bellevue Hospital and the Manhattan VA and an Associate Clinical Professor of Ophthalmology at New York University. He currently holds the titles of Associate Clinical Professor of Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai and Associate Clinical Professor of Medicine at Frank H. Netter School of Medicine at Quinnipiac University. To date, Dr. Farris has helped train over one hundred and fifty ophthalmic residents and fellows. Dr. Farris has lectured extensively throughout the country on numerous topics related to glaucoma and his scientific papers have been published in national and international journals. He is proud to have been named among the Best Doctors in America as well as one of America’s Top Ophthalmologists on numerous occasions. He is a consultant to major ophthalmic pharmaceutical companies, helping to further advance the medical and surgical treatment of glaucoma.